Protein Name2 Protein MW (Da)3 Protein pI4 MS/MS
Search Score5		 Distinct Peptides6 Spectral Intensity (x107) for respective patients ID7
1-A 3-B 5-C 8-D
Apolipoprotein B precursor 515533.1 6.58 640.05 49 5.96 16.8 17.2 4.20
Complement component 4A 192788.6 6.72 298.16 21 22.3 25.5 21.0 4.99
Ceruloplasmin 123002.7 5.46 281.99 19 35.1 27.7 51.3 9.77
Fibronectin 1 272337.8 5.3 210.73 16 4.83 6.28 11.9 1.71
Inter-alpha-trypsin inhibitor family heavy chain-related protein 103385.9 6.51 153.9 11 40.6 33.2 29.9 4.53
Inter-alpha inhibitor H1 101366.7 6.43 143.71 10 8.85 13.5 9.96 3.81
Hemopexin 51676.7 6.55 140.64 9 39.3 61.8 48.2 18.6
Apolipoprotein A-1 preproprotein 30778 5.56 117.16 7 3.33 39.3 27.9 11.7
Beta-2-glycoprotein 1 apolipoprotein H 38312.5 8.34 101.84 7 87.9 41.2 70.6 6.05
Alpha-1B-glycoprotein precursor 54272.8 5.58 100.81 7 26.9 32.3 34.1 7.33
Angiotensinogen precursor variant 53778.2 5.97 87.81 6 36.9 36.8 71.6 6.26

1LC-MS/MS Spectrum Mill database-search for plasma samples obtained from control obese and/or diabetic patients.
2List of the protein.
3Theoretical MW (Da) of the identified protein from the database.
4Theoretical isolelectric points (pI) of the identified protein from the database.
5MS/MS search score is computed by scoring function that measure the degree of similarity between the experimental spectrum and the theoretical fragmentation patterns of the candidate peptides.
6Number of the distinct peptides of the protein after fragmentation and is based on the homology of the protein with the known protein in the database.
7The intensity fold increase of the spectra in the sample is calculated by the factor 1x107.

Table 2: Identification of candidate biomarkers linking obesity and diabetes1